PATENT CLAIM ANALYSIS

Application Number: 15744278
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["424", "134100"]

Abstract:
Disclosed is a fusion polypeptide for inhibiting neovascularization, including a peptide specifically binding to vascular endothelial growth factor (VEGF) receptors, and a hydrophilic elastin-based polypeptide (hydrophilic EBP) linked to the peptide.

Claim (Index 6):
The fusion polypeptide according to  claim 4 , wherein the hydrophilic EBP is consisted of an amino acid sequence represented by Formula 2:\n in Formula 2, n is 3, 6, 12 or 24, and the pentapeptide repeats correspond to SEQ ID NO. 41, SEQ ID NO. 42, SEQ ID NO. 43 or SEQ ID NO. 44 and each X of the pentapeptide repeats is consisted of A (Ala), G (Gly), and I (Ile) in a ratio of 1:4:1, or in Formula 2, n is 12, and the pentapeptide repeats correspond to [SEQ ID NO. 45] and each X of the pentapeptide repeats is consisted of E (Glu), G (Gly), and I (Ile) in a ratio of 1:4:1.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 86.0
- Lexical Diversity: 1.31034
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14917460', '14740194', '12789215', '14740158', '14442376']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7366963472915533
- 35 USC 102 Novelty (BERT): 0.5248083326700137
- Combined Prediction Score: 0.7155075458293993
- Mean Citation Score: 259.111848
- Max Citation Score: 305.7306
- Similarity Product: 201.502681976223

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test